Results 71 to 80 of about 14,336,962 (399)
Weak proton capture on 3He [PDF]
, 2000 The astrophysical S-factor for the proton weak capture on 3He is calculated with correlated-hyperspherical-harmonics bound and continuum wave functions corresponding to realistic Hamiltonians consisting of the Argonne v14 or Argonne v18 two-nucleon and ...
Beacom, J. F. +5 more
core +2 more sources
Recombinant Factor VIII Concentrates [PDF]
Seminars in Thrombosis and Hemostasis, 2010 The development and introduction of recombinant factor VIII (rFVIII) concentrates nearly 20 years ago represented a major advance in the treatment of hemophilia A patients. Currently, first-, second- and third-generation rFVIII products are commercially available.
Franchini M, LIPPI, Giuseppe
openaire +5 more sources
Molecular Oncology, EarlyView.Combining melting curve analysis enhances the multiplexing capability of digital PCR. Here, we developed a 14‐plex assay to simultaneously measure single nucleotide mutations and amplifications of KRAS and GNAS, which are common driver genes in pancreatic cancer precursors. This assay accurately quantified variant allele frequencies in clinical samples
Junko Tanaka +10 more
wiley +1 more source
Haematologica, 2010 Background Pregnancy in von Willebrand’s disease may carry a significant risk of bleeding. Information on changes in factor VIII and von Willebrand factor and pregnancy outcome in relation to von Willebrand factor gene mutations are very scanty.Design ...
Giancarlo Castaman +2 more
doaj +1 more source
Tolerating Factor VIII: Recent Progress
Frontiers in Immunology, 2020 Development of neutralizing antibodies against biotherapeutic agents administered to prevent or treat various clinical conditions is a longstanding and growing problem faced by patients, medical providers and pharmaceutical companies.
Sebastien Lacroix-Desmazes +4 more
doaj +1 more source
Molecular Oncology, EarlyView.Chronic TGF‐β exposure drives epithelial HCC cells from a senescent state to a TGF‐β resistant mesenchymal phenotype. This transition is characterized by the loss of Smad3‐mediated signaling, escape from senescence, enhanced invasiveness and metastatic potential, and upregulation of key resistance modulators such as MARK1 and GRM8, ultimately promoting
Minenur Kalyoncu +11 more
wiley +1 more source
In Vitro Modeling of the Influence of FVIII Activity and Heparin Induced Prolongation of APTT
Biomolecules & Biomedicine, 2008 Anticoagulant therapy is most commonly assessed by measuring the effect of the drug on global clotting assay, such as APTT. It is known that response of the APTT to hepa-rin may be decreased in patients with high levels of factor VIII.
Aida Mehmedagić +3 more
doaj +1 more source
Light-front model of the kaon electromagnetic current [PDF]
, 2002 The electromagnetic form factor is extracted from both components of the electromagnetic current: J(plus) and J(minus) with a pseudo-scalar coupling of the quarks to the kaon.
de Melo, J. P. B. C. +2 more
core +2 more sources
Role of Factor VIII C2 Domain in Factor VIII Binding to Factor Xa [PDF]
Journal of Biological Chemistry, 1999 Factor VIII (FVIII) is activated by proteolytic cleavages with thrombin and factor Xa (FXa) in the intrinsic blood coagulation pathway. The anti-C2 monoclonal antibody ESH8, which recognizes residues 2248-2285 and does not inhibit FVIII binding to von Willebrand factor or phospholipid, inhibited FVIII activation by FXa in a clotting assay. Furthermore,
Kazuya Hosokawa +10 more
openaire +3 more sources
Blood, 2014 The effect of recombinant factor VIII (rFVIII) brand on inhibitor development was investigated in all 407 severe hemophilia A previously untreated patients born in the United Kingdom (UK) between 1 January 2000 and 31 December 2011.
P. Collins +8 more
semanticscholar +1 more source